RTTNews BiotechCodex · 实盘不做把握 6/10
北京时间·🕒 发布 17:10:42时区推断·⟳ 抓取 17:15:22·⚡ 决策 07-28 17:18:18 +2m56s·91.1 天前
阿斯利康与康诺亚Sone-Ve胃癌三期达到总生存终点但PFS未达显著
Sone-Ve在CLDN18.2阳性二线及后线胃癌三期中证明OS获益，是CLDN18.2 ADC全球注册性临床的重要进展。
📄 原文RTTNews Biotech↗ 原文
AstraZeneca's Sone-Ve Improves Survival In Gastric Cancer Trial
Business Latest Headlines Top Stories Breaking News Earnings Biotech Investors Stock Alerts IPOs M&A Canadian UK Wallst…
不做 康诺亚-B（02162.HK）
核心临床进展已于7月27日披露并被港股完整交易，且02162.HK当日收跌5.16%，PFS未达标削弱单边利好，不做追多。
不做 乐普生物-B（02157.HK）
虽有合作权益和当日上涨，但经济分成/里程碑量级未充分坐实，且消息已传播并交易一日，当前没有清晰剩余edge。
不做 阿斯利康（AZN.US）
阿斯利康为超大市值药企，单一管线阳性且无销售金额或利润增量披露，对短线市值弹性不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 阿斯利康官方披露Sone-Ve在CLARITY-Gastric01三期中达到3L+ OS主要终点和2L+ OS关键次要终点，但2L+ PFS未达统计学显著。
- 英文财经媒体在7月27日早间已报道该临床结果，说明并非7月28日RTTNews首发。
- 2026-07-28 09:15 UTC市场反应Futu/stock_quote非一手康诺亚-B（02162.HK）当日收报78.05港元，跌5.16%；乐普生物-B（02157.HK）涨3.38%，显示事件已被港股消化且主权益方反应偏负。市场反应:02162.HK -5.16%，02157.HK +3.38%
关键理由
- Sone-Ve在CLDN18.2阳性二线及后线胃癌三期中证明OS获益，是CLDN18.2 ADC全球注册性临床的重要进展。
- 但另一双主要终点PFS仅显示改善趋势、未达统计学显著，削弱了短线单边利好质量。
- 事件最早已在2026-07-27由阿斯利康官方披露并被券商/财经媒体扩散，港股02162.HK和02157.HK已完整交易一日，不再是未反应窗口。
主要风险
- 康诺亚-B（02162.HK）当日收跌5.16%，说明港股市场没有按单纯利好重定价，可能在交易PFS未达标或兑现预期。
- 后续仍需等待完整医学会议数据和监管递交节奏，当前没有披露HR、mOS等关键量化数据，难以估算短线新增估值空间。
反向证据
- 做多前查反向 · 来源 kb_search · 日期 2026-07-28 · 影响 weakens
内部库命中券商称峰值销售指引30-50亿美元超预期，但同时反复提到2L+ PFS未达统计学显著，且7月27日已有覆盖。
检索:康诺亚 02162 CMG901 Sone-Ve 销售峰值 30-50亿美元 70% KYM 里程碑 royalty 反向 PFS 未达 原文 ↗ - 做多前查反向 · 来源 kb_search · 日期 2026-07-27 · 影响 weakens
内部库确认乐普生物与康诺亚/阿斯利康相关，但未给出足够清晰的分成、里程碑和产品收入占比来支持追高。
检索:乐普生物 02157 CMG901 KYM 30% milestone royalty Sone-Ve 胃癌 三期 原文 ↗
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 8,374 字
AstraZeneca's Sone-Ve Improves Survival In Gastric Cancer Trial
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Blockchain
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
World
White House
Elections
General News
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Corp. News
Market News
Health News
Entertainment News
Music News
Biotech Daily Dose
By
TajSabreen Ahamed
✉
|
Published:
7/28/2026 5:10 AM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
AstraZeneca (
AZN
) and Keymed Biosciences (
2162.HK
), through their joint venture with Lepu Biopharma, announced that the antibody drug conjugate Sonesitatug vedotin (Sone-Ve) demonstrated a statistically significant and clinically meaningful improvement in overall survival for patients with advanced gastric cancers and gastroesophageal junction cancers.
The results came from a pivotal late-stage trial in CLDN18.2-positive patients who had received at least two prior lines of therapy.
The trial was designed with dual primary goals: overall survival in patients receiving third line and later treatment, and progression-free survival across the full trial population. It successfully achieved the survival benefit in the third line and later setting, while also demonstrating a key secondary endpoint of improved overall survival in the broader group of patients treated in the second line and later setting. These results confirm a statistically significant and clinically meaningful benefit.
For the other dual primary endpoint of progression-free survival, as assessed by blinded independent central review, results showed a trend toward improvement in patients treated in the second line and later setting, but this did not reach statistical significance.
AstraZeneca highlighted that these findings reinforce the promise of targeted therapies in hard-to-treat gastrointestinal cancers, where treatment options remain limited.
Keymed Biosciences, listed in Hong Kong, collaborated closely with AstraZeneca to advance the program. Lepu Biopharma contributed to the joint venture, underscoring the multinational effort behind the development.
Gastric cancer remains one of the leading causes of cancer mortality, worldwide, particularly in Asia. The positive survival data from Sone-Ve offers hope for patients with CLDN18.2-positive tumors, a subgroup that has historically faced poor outcomes.
Sone-Ve is a potential first-in-class CLDN18.2-targeting antibody drug conjugate (ADC) with a monomethyl auristatin E (MMAE) payload. It has received Orphan Drug Designation from both the U.S. FDA and the European Commission for the treatment of gastric and gastroesophageal junction cancers. In China, it has also been granted Breakthrough Therapy Designation for second-line treatment of gastric cancer.
AstraZeneca noted that further data will be presented at a forthcoming medical meeting and shared with global regulatory authorities.
AZN has traded between $142.98 and $212.71 over the past year. The stock closed Monday's trading at $169.64, up 0.22%. In pre-market trading the stock is at $168.69, down 0.59%.
For comments and feedback contact: editorial@rttnews.com
Business News
Biotech Stocks Facing FDA Decision In July 2026
Biotech Stocks Facing FDA Decision In June 2026
Biotech Stocks Facing FDA Decision In May 2026
Latest Updates on Middle East War
U.S. Dollar Ticks Higher As Easing Middle East Tensions Lowers Fed Rate Hike Expectations
July 27, 2026 17:00 ET
Canadian Stocks Edge Higher Amid Easing Middle East Tensions
July 27, 2026 16:26 ET
Crude Oil Nosedives As Middle East Tension Eases After U.S. And Iran Pause Mutual Attacks
July 27, 2026 14:36 ET
Gold Inches Higher As Middle East Tensions Ease, Crude Oil Plunges Sharply
July 27, 2026 13:40 ET
U.S. Dollar Ticks Higher As U.S. Steps Up Threats On Iran While Crude Oil Prices Plunge
July 24, 2026 17:00 ET
View More
Global Economics Weekly Update - July 20 – July 24, 2026
July 25, 2026 02:46 ET
The latest policy decision from the European Central Bank dominated the scene this week that was relatively slow for economics news flow. In the U.S., main highlights were the weekly initial jobless claims and new home sales data. In Europe, the ECB rate decision and the latest inflation figures from the U.K. drew attention. In Asia, results of a private sector survey from India were in focus.
View More Videos
RELATED NEWS
AstraZeneca's Ultomiris HSCT-TMA Trial Shows Mixed Results; Pediatric Data Show Survival Benefit
AstraZeneca Q2 Pre-tax Profit Down, But EPS Rise; Backs Positive FY26 View
AstraZeneca Q2 Pre-tax Profit Drops, Revenues Rise; Confirms FY26 Outlook
AstraZeneca Q2 Earnings Preview: Can Tagrisso, Imfinzi And Farxiga Sustain Momentum?
Weekly Buzz: AZN, GSK JNJ Approvals; CUV Layoff, REGN, HALO, Samsun Deals, LLY, CLDX Data
Latest Updates on COVID-19
KFF Poll Finds AI Health Chatbot Users More Likely To Believe Vaccine Myths
July 01, 2026 14:27 ET
Editor's Pick
Most Read
Most Emailed
July 27, 2026 04:19 ET
Verizon Lifts FY26 View Despite Weak Q2, Expands Buyback To Up To $4.5 Bln; Shares Up
July 24, 2026 10:21 ET
EU Commission Flags TikTok's Minor Account Safety Gaps
July 24, 2026 09:56 ET
Volkswagen Cuts FY26 Revenue View After Weak Q2 Profit, Volume
July 24, 2026 05:33 ET
T-Mobile US Q2 Profit Edges Up, Net Additions Drop, Backs FY26 View; Stock Down
July 23, 2026 09:43 ET
WSP Raises Arcadis Acquisition Offer To €51.50 After Initial Rejection
July 24, 2026 11:50 ET
Amapá Minerals Reveals Pricing Of IPO Of 127.27 Mln Common Shares At $1.10/Shr
July 24, 2026 01:42 ET
Union Pacific Signs MoU With CN Supporting Proposed Norfolk Southern Merger
July 23, 2026 01:19 ET
Eligible Amazon Prime Members Have Until July 27 To Claim Up To $51 In FTC Settlement
July 24, 2026 17:15 ET
ATOSS H1 Profit Rises On Higher Revenue; Maintains FY26, FY27 Forecast
July 24, 2026 02:41 ET
Safety Insurance To Be Acquired By Mapfre In $1.54 Bln All-Cash Deal
July 23, 2026 17:11 ET
Nestlé SA H1 Profit Declines, Confirms FY26 Outlook
July 23, 2026 02:21 ET
Carpenter Technology CEO Brian Malloy Passes Away; Tony Thene Named CEO
July 27, 2026 08:18 ET
Argenx To Buy Forte Biosciences In Around $2.2 Bln Cash Deal; Forte Biosciences Shares Climb
July 27, 2026 01:24 ET
Westports Holdings Berhad Bottom Line Advances In Q2
July 23, 2026 00:56 ET
West Bancorporation Inc. Reveals Rise In Q2 Profit
July 23, 2026 09:02 ET
SFS Group AG H1 Income Rises
July 23, 2026 00:58 ET
NVR Inc. Bottom Line Declines In Q2
July 23, 2026 09:05 ET
Cembra Money Bank AG Announces Increase In H1 Income
July 23, 2026 01:02 ET
ACNB Corporation Reports Increase In Q2 Bottom Line
July 23, 2026 09:07 ET
Givaudan H1 Profit, Sales Down; Backs LFL Sales Growth View Ahead
July 23, 2026 01:03 ET
Mapletree Industrial Trust Profit Drops In Q1
July 23, 2026 09:11 ET
Pihlajalinna Oyj Bottom Line Falls In Q2
July 23, 2026 01:07 ET
Kearny Financial Corp. Q4 Sales Increase
July 23, 2026 09:16 ET
LS ELECTRIC Q2 Operating Income Rises
July 23, 2026 01:17 ET
Mapletree Industrial Trust Q1 Profit Drops
July 23, 2026 09:23 ET
Editors Pick
Loading...
Copyright © 2026 RTTNews. All rights reserved.
By using this site, you agree to the
Terms of Service
.
About Us
Privacy
Sitemap
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Blockchain
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
World
White House
Elections
General News
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Corp. News
Market News
Health News
Entertainment News
Music News
Biotech Daily Dose
By
TajSabreen Ahamed
✉
|
Published:
7/28/2026 5:10 AM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
AstraZeneca (
AZN
) and Keymed Biosciences (
2162.HK
), through their joint venture with Lepu Biopharma, announced that the antibody drug conjugate Sonesitatug vedotin (Sone-Ve) demonstrated a statistically significant and clinically meaningful improvement in overall survival for patients with advanced gastric cancers and gastroesophageal junction cancers.
The results came from a pivotal late-stage trial in CLDN18.2-positive patients who had received at least two prior lines of therapy.
The trial was designed with dual primary goals: overall survival in patients receiving third line and later treatment, and progression-free survival across the full trial population. It successfully achieved the survival benefit in the third line and later setting, while also demonstrating a key secondary endpoint of improved overall survival in the broader group of patients treated in the second line and later setting. These results confirm a statistically significant and clinically meaningful benefit.
For the other dual primary endpoint of progression-free survival, as assessed by blinded independent central review, results showed a trend toward improvement in patients treated in the second line and later setting, but this did not reach statistical significance.
AstraZeneca highlighted that these findings reinforce the promise of targeted therapies in hard-to-treat gastrointestinal cancers, where treatment options remain limited.
Keymed Biosciences, listed in Hong Kong, collaborated closely with AstraZeneca to advance the program. Lepu Biopharma contributed to the joint venture, underscoring the multinational effort behind the development.
Gastric cancer remains one of the leading causes of cancer mortality, worldwide, particularly in Asia. The positive survival data from Sone-Ve offers hope for patients with CLDN18.2-positive tumors, a subgroup that has historically faced poor outcomes.
Sone-Ve is a potential first-in-class CLDN18.2-targeting antibody drug conjugate (ADC) with a monomethyl auristatin E (MMAE) payload. It has received Orphan Drug Designation from both the U.S. FDA and the European Commission for the treatment of gastric and gastroesophageal junction cancers. In China, it has also been granted Breakthrough Therapy Designation for second-line treatment of gastric cancer.
AstraZeneca noted that further data will be presented at a forthcoming medical meeting and shared with global regulatory authorities.
AZN has traded between $142.98 and $212.71 over the past year. The stock closed Monday's trading at $169.64, up 0.22%. In pre-market trading the stock is at $168.69, down 0.59%.
For comments and feedback contact: editorial@rttnews.com
Business News
Biotech Stocks Facing FDA Decision In July 2026
Biotech Stocks Facing FDA Decision In June 2026
Biotech Stocks Facing FDA Decision In May 2026
Latest Updates on Middle East War
U.S. Dollar Ticks Higher As Easing Middle East Tensions Lowers Fed Rate Hike Expectations
July 27, 2026 17:00 ET
Canadian Stocks Edge Higher Amid Easing Middle East Tensions
July 27, 2026 16:26 ET
Crude Oil Nosedives As Middle East Tension Eases After U.S. And Iran Pause Mutual Attacks
July 27, 2026 14:36 ET
Gold Inches Higher As Middle East Tensions Ease, Crude Oil Plunges Sharply
July 27, 2026 13:40 ET
U.S. Dollar Ticks Higher As U.S. Steps Up Threats On Iran While Crude Oil Prices Plunge
July 24, 2026 17:00 ET
View More
Global Economics Weekly Update - July 20 – July 24, 2026
July 25, 2026 02:46 ET
The latest policy decision from the European Central Bank dominated the scene this week that was relatively slow for economics news flow. In the U.S., main highlights were the weekly initial jobless claims and new home sales data. In Europe, the ECB rate decision and the latest inflation figures from the U.K. drew attention. In Asia, results of a private sector survey from India were in focus.
View More Videos
RELATED NEWS
AstraZeneca's Ultomiris HSCT-TMA Trial Shows Mixed Results; Pediatric Data Show Survival Benefit
AstraZeneca Q2 Pre-tax Profit Down, But EPS Rise; Backs Positive FY26 View
AstraZeneca Q2 Pre-tax Profit Drops, Revenues Rise; Confirms FY26 Outlook
AstraZeneca Q2 Earnings Preview: Can Tagrisso, Imfinzi And Farxiga Sustain Momentum?
Weekly Buzz: AZN, GSK JNJ Approvals; CUV Layoff, REGN, HALO, Samsun Deals, LLY, CLDX Data
Latest Updates on COVID-19
KFF Poll Finds AI Health Chatbot Users More Likely To Believe Vaccine Myths
July 01, 2026 14:27 ET
Editor's Pick
Most Read
Most Emailed
July 27, 2026 04:19 ET
Verizon Lifts FY26 View Despite Weak Q2, Expands Buyback To Up To $4.5 Bln; Shares Up
July 24, 2026 10:21 ET
EU Commission Flags TikTok's Minor Account Safety Gaps
July 24, 2026 09:56 ET
Volkswagen Cuts FY26 Revenue View After Weak Q2 Profit, Volume
July 24, 2026 05:33 ET
T-Mobile US Q2 Profit Edges Up, Net Additions Drop, Backs FY26 View; Stock Down
July 23, 2026 09:43 ET
WSP Raises Arcadis Acquisition Offer To €51.50 After Initial Rejection
July 24, 2026 11:50 ET
Amapá Minerals Reveals Pricing Of IPO Of 127.27 Mln Common Shares At $1.10/Shr
July 24, 2026 01:42 ET
Union Pacific Signs MoU With CN Supporting Proposed Norfolk Southern Merger
July 23, 2026 01:19 ET
Eligible Amazon Prime Members Have Until July 27 To Claim Up To $51 In FTC Settlement
July 24, 2026 17:15 ET
ATOSS H1 Profit Rises On Higher Revenue; Maintains FY26, FY27 Forecast
July 24, 2026 02:41 ET
Safety Insurance To Be Acquired By Mapfre In $1.54 Bln All-Cash Deal
July 23, 2026 17:11 ET
Nestlé SA H1 Profit Declines, Confirms FY26 Outlook
July 23, 2026 02:21 ET
Carpenter Technology CEO Brian Malloy Passes Away; Tony Thene Named CEO
July 27, 2026 08:18 ET
Argenx To Buy Forte Biosciences In Around $2.2 Bln Cash Deal; Forte Biosciences Shares Climb
July 27, 2026 01:24 ET
Westports Holdings Berhad Bottom Line Advances In Q2
July 23, 2026 00:56 ET
West Bancorporation Inc. Reveals Rise In Q2 Profit
July 23, 2026 09:02 ET
SFS Group AG H1 Income Rises
July 23, 2026 00:58 ET
NVR Inc. Bottom Line Declines In Q2
July 23, 2026 09:05 ET
Cembra Money Bank AG Announces Increase In H1 Income
July 23, 2026 01:02 ET
ACNB Corporation Reports Increase In Q2 Bottom Line
July 23, 2026 09:07 ET
Givaudan H1 Profit, Sales Down; Backs LFL Sales Growth View Ahead
July 23, 2026 01:03 ET
Mapletree Industrial Trust Profit Drops In Q1
July 23, 2026 09:11 ET
Pihlajalinna Oyj Bottom Line Falls In Q2
July 23, 2026 01:07 ET
Kearny Financial Corp. Q4 Sales Increase
July 23, 2026 09:16 ET
LS ELECTRIC Q2 Operating Income Rises
July 23, 2026 01:17 ET
Mapletree Industrial Trust Q1 Profit Drops
July 23, 2026 09:23 ET
Editors Pick
Loading...
Copyright © 2026 RTTNews. All rights reserved.
By using this site, you agree to the
Terms of Service
.
About Us
Privacy
Sitemap
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。